Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

Purpose Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV. FOLFIRI requires a CV catheter and an infusion pump,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2017-03, Vol.79 (3), p.579-585
Hauptverfasser:	Kuramochi, Hidekazu, Ando, Masayuki, Itabashi, Michio, Nakajima, Go, Kawakami, Kazuyuki, Hamano, Mie, Hirai, Eiichi, Yokomizo, Hajime, Okuyama, Ryuji, Araida, Tatsuo, Yoshimatsu, Kazuhiko, Kameoka, Shingo, Hayashi, Kazuhiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Antimetabolites, Antineoplastic - administration & dosage Antineoplastic Agents - administration & dosage Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cancer Research Colorectal Neoplasms - drug therapy Disease-Free Survival Endpoint Determination Female Fluorouracil - administration & dosage Humans Leucovorin - administration & dosage Male Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis - drug therapy Oncology Organoplatinum Compounds - administration & dosage Original Article Pharmacology/Toxicology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!